ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2504

A More Time Under Remission Impacts in a Better Health-Related Quality of Life in Rheumatoid Arthritis Mestizo Population

Rocío Gamboa-Cárdenas1, Manuel Ugarte-Gil2,3, Mariela Medina-Chinchon1, Cristina Reategui-Sokolova1, Francisco Zevallos1, Victor R. Pimentel-Quiroz1, Claudia Elera-Fitzcarrald1,4, Jose Alfaro-Lozano1, Zoila Rodriguez-Bellido1,5, Risto Perich-Campos1,5 and Cesar A. Pastor-Asurza1,5, 1Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 2Rheumatology, Universidad Científica del Sur, Lima, Peru, 3Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 4Universidad Científica del Sur, Lima, Peru, 5Universidad Nacional Mayor de San Marcos, Lima, Peru

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Clinical Response, Disability and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: In Rheumatoid Arthritis (RA), sustained remission is associated with less disability (1,2) , and this outcome should be the goal in the RA treatment; however, there are scarce of data about the impact of prolonged remission in health-related quality of life (HRQoL) in RA patients in our region. The aim of this study is to determine the impact of time under remission in to achieve a better HRQol status in RA

Methods: Prospective study in a RA cohort from a single center. Subjects with at least two visits performed, were included. Visits were performed every six months; socio-demographic, clinical data (including disease activity status) and HRQol measured by the 36-Item Short Form Health Survey questionnaire(SF36), were recorded in each visit. Remission and low disease activity (LDA) statuses were defined as Clinical Disease Activity Index (CDAI) definition(<2.8 and 2.9-10, respectively) and time in remission was categorized in percentiles of time (>50, >25% and ≤50%, and ≤25%) in remission. The outcome was the value of each SF36 component and domain at the final visit. Univariable and multivariable lineal regression models, adjusted by age at diagnosis, disease duration, treatment [use of corticosteroid, synthetic(s) and biologic (b) Disease Modifying Rheumatic Drugs (DMARDs)], time of follow up and each baseline SF36 component or domain were performed in order to determine the associations.

Results: Four hundred nine patients were included; 369 (90.2%) were female, age at diagnosis was 44.49 (13.84)years and disease duration at baseline was 16.57(11.50) years. sDMARDs and bDMARDs were used at baseline by 58,7% and 9.5% respectively. The mean follow-up was 1.39(0.49) years. Percentage of time under remission and LDA status during the follow up were 13.33(26.39)and 49.61(39.16)respectively. In the multivariable analysws the better percentile under remission (>50%) predicted a better HQol performance in the Physical Component Summary(PCS): B=0.170(0.705-1.635);P<0.001, and in the following components: physical functioning [B=0.078; (0.033; 0.122); p<0.001], role physical [B=0.215 (0.163-0.267); p<0.001], body image [B=0.293; (0.251-0.335); p<0.001]; global health [B=0.127 (0.083-0.171);p=0.001]; role emotional [B=0.184 (0.126-0.242); p<0.001]; mental health [B=0.051; (0.011-0.091); p=0.012]. There were not statistically significant associations with the other component and domains.

Conclusion: A more prolonged time under remission predicted a better HQol status in our RA patients. Prolonged remission in addition with sustained remission could be a treatment goal to avoid disability.

(1). Einarson JT. J Rheumatol. 2016;43(6):1017-23. (2). Ma MHY. Clin Exp Rheumatol. 2018; 36(2):203-209


Disclosure: R. Gamboa-Cárdenas, None; M. Ugarte-Gil, None; M. Medina-Chinchon, None; C. Reategui-Sokolova, None; F. Zevallos, None; V. R. Pimentel-Quiroz, None; C. Elera-Fitzcarrald, None; J. Alfaro-Lozano, None; Z. Rodriguez-Bellido, None; R. Perich-Campos, None; C. A. Pastor-Asurza, None.

To cite this abstract in AMA style:

Gamboa-Cárdenas R, Ugarte-Gil M, Medina-Chinchon M, Reategui-Sokolova C, Zevallos F, Pimentel-Quiroz VR, Elera-Fitzcarrald C, Alfaro-Lozano J, Rodriguez-Bellido Z, Perich-Campos R, Pastor-Asurza CA. A More Time Under Remission Impacts in a Better Health-Related Quality of Life in Rheumatoid Arthritis Mestizo Population [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/a-more-time-under-remission-impacts-in-a-better-health-related-quality-of-life-in-rheumatoid-arthritis-mestizo-population/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-more-time-under-remission-impacts-in-a-better-health-related-quality-of-life-in-rheumatoid-arthritis-mestizo-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology